PE20171620A1 - Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas - Google Patents
Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricasInfo
- Publication number
- PE20171620A1 PE20171620A1 PE2017002102A PE2017002102A PE20171620A1 PE 20171620 A1 PE20171620 A1 PE 20171620A1 PE 2017002102 A PE2017002102 A PE 2017002102A PE 2017002102 A PE2017002102 A PE 2017002102A PE 20171620 A1 PE20171620 A1 PE 20171620A1
- Authority
- PE
- Peru
- Prior art keywords
- sulfonimidoylpurinone
- prophylaxis
- treatment
- viric
- infections
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 208000015181 infectious disease Diseases 0.000 title abstract 2
- 238000011321 prophylaxis Methods 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 102000002689 Toll-like receptor Human genes 0.000 abstract 2
- 108020000411 Toll-like receptor Proteins 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- WLAWDJREXFPHPH-VWLOTQADSA-N 6-amino-9-[(4-chlorophenyl)methyl]-2-(propylsulfonimidoyl)-7H-purin-8-one Chemical compound C(C1=CC=C(Cl)C=C1)N1C2=C(C(=NC([S@](=O)(=N)CCC)=N2)N)NC1=O WLAWDJREXFPHPH-VWLOTQADSA-N 0.000 abstract 1
- XFDVJIPIVPRMJX-UHFFFAOYSA-N 6-amino-9-benzyl-2-(ethylsulfonimidoyl)-7H-purin-8-one Chemical compound NC1=C2NC(N(C2=NC(=N1)S(=O)(=N)CC)CC1=CC=CC=C1)=O XFDVJIPIVPRMJX-UHFFFAOYSA-N 0.000 abstract 1
- 241000700721 Hepatitis B virus Species 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2015078507 | 2015-05-08 | ||
| CN2016078785 | 2016-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20171620A1 true PE20171620A1 (es) | 2017-11-02 |
Family
ID=55910966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017002102A PE20171620A1 (es) | 2015-05-08 | 2016-05-04 | Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US9708325B2 (https=) |
| EP (1) | EP3294740B1 (https=) |
| JP (1) | JP6738352B2 (https=) |
| KR (1) | KR102690131B1 (https=) |
| CN (1) | CN107580596B (https=) |
| AR (1) | AR104528A1 (https=) |
| AU (3) | AU2016260683B2 (https=) |
| BR (1) | BR112017023959B1 (https=) |
| CA (1) | CA2982704C (https=) |
| CL (1) | CL2017002745A1 (https=) |
| CO (1) | CO2017009994A2 (https=) |
| CR (1) | CR20170496A (https=) |
| DK (1) | DK3294740T3 (https=) |
| ES (1) | ES2753777T3 (https=) |
| HR (1) | HRP20191942T1 (https=) |
| HU (1) | HUE045906T2 (https=) |
| IL (2) | IL254947B (https=) |
| LT (1) | LT3294740T (https=) |
| MX (2) | MX376761B (https=) |
| MY (1) | MY182353A (https=) |
| NZ (2) | NZ775222A (https=) |
| PE (1) | PE20171620A1 (https=) |
| PH (1) | PH12017502009A1 (https=) |
| PL (1) | PL3294740T3 (https=) |
| PT (1) | PT3294740T (https=) |
| RS (1) | RS59435B1 (https=) |
| RU (1) | RU2745269C2 (https=) |
| SG (1) | SG10202108841YA (https=) |
| SI (1) | SI3294740T1 (https=) |
| TW (2) | TWI706954B (https=) |
| UA (1) | UA120450C2 (https=) |
| WO (1) | WO2016180695A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3294740T3 (pl) * | 2015-05-08 | 2020-03-31 | F. Hoffmann-La Roche Ag | Nowe sulfonoimidoilopurynony i pochodne do leczenia i profilaktyki infekcji wirusowych |
| AU2017320742B2 (en) | 2016-08-29 | 2021-08-05 | F. Hoffmann-La Roche Ag | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection |
| CN109715214B (zh) | 2016-09-13 | 2022-03-04 | 豪夫迈·罗氏有限公司 | Tlr7激动剂和hbv衣壳组装抑制剂的组合治疗 |
| JP7328977B2 (ja) | 2018-02-12 | 2023-08-17 | エフ． ホフマン－ラ ロシュ アーゲー | ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体 |
| RU2020131012A (ru) * | 2018-02-28 | 2022-03-28 | Ф. Хоффманн-Ля Рош Аг | 7-замещенные соединения сульфонимидоилпуринонов и их производные для лечения и профилактики рака печени |
| CN111072667A (zh) * | 2018-10-22 | 2020-04-28 | 罗欣药业(上海)有限公司 | 五元或六元杂环并嘧啶类化合物及其用途 |
| JP7695885B2 (ja) * | 2019-02-12 | 2025-06-19 | アンブルックス，インコーポレイテッド | 抗体－ｔｌｒアゴニストコンジュゲートを含有する組成物、その方法、及び使用 |
| JP7581336B2 (ja) | 2019-09-20 | 2024-11-12 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 硫黄及びスルホキシミン含有置換基を有する殺有害生物的に活性な複素環式誘導体 |
| US20230131192A1 (en) * | 2020-01-27 | 2023-04-27 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| JP2023512204A (ja) * | 2020-01-27 | 2023-03-24 | ブリストル－マイヤーズ スクイブ カンパニー | トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物 |
| CN119604517A (zh) | 2022-07-14 | 2025-03-11 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的磷酰基嘌呤酮化合物 |
| CN118724963A (zh) * | 2023-03-30 | 2024-10-01 | 浙江养生堂天然药物研究所有限公司 | 含磷或含硫的大环化合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4189048B2 (ja) * | 1997-12-26 | 2008-12-03 | 大日本住友製薬株式会社 | 複素環化合物 |
| EP1888587A1 (en) | 2005-05-04 | 2008-02-20 | Pfizer Limited | 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c |
| CN101239980B (zh) | 2008-02-18 | 2011-06-22 | 靳广毅 | 免疫受体调节剂偶联体前体和偶联体及其应用 |
| ES2467108T3 (es) * | 2008-12-09 | 2014-06-11 | Gilead Sciences, Inc. | Moduladores de receptores tipo toll |
| WO2011079016A1 (en) | 2009-12-22 | 2011-06-30 | Gilead Sciences, Inc. | Methods of treating hbv and hcv infection |
| TW201636330A (zh) * | 2011-05-24 | 2016-10-16 | 拜耳知識產權公司 | 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺 |
| RS57851B1 (sr) * | 2011-11-09 | 2018-12-31 | Janssen Sciences Ireland Uc | Purinski derivati za tretman viralnih infekcija |
| AU2014242954B2 (en) | 2013-03-29 | 2018-03-15 | Janssen Sciences Ireland Uc | Macrocyclic deaza-purinones for the treatment of viral infections |
| HUE054672T2 (hu) | 2014-08-15 | 2021-09-28 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | TLR7 agonistaként alkalmazott pirrolopirimidin vegyületek |
| PL3294740T3 (pl) * | 2015-05-08 | 2020-03-31 | F. Hoffmann-La Roche Ag | Nowe sulfonoimidoilopurynony i pochodne do leczenia i profilaktyki infekcji wirusowych |
| AU2017320742B2 (en) * | 2016-08-29 | 2021-08-05 | F. Hoffmann-La Roche Ag | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection |
-
2016
- 2016-05-04 PL PL16720421T patent/PL3294740T3/pl unknown
- 2016-05-04 RU RU2017142577A patent/RU2745269C2/ru active
- 2016-05-04 BR BR112017023959-0A patent/BR112017023959B1/pt not_active IP Right Cessation
- 2016-05-04 SG SG10202108841YA patent/SG10202108841YA/en unknown
- 2016-05-04 NZ NZ775222A patent/NZ775222A/en unknown
- 2016-05-04 MY MYPI2017704175A patent/MY182353A/en unknown
- 2016-05-04 AU AU2016260683A patent/AU2016260683B2/en not_active Ceased
- 2016-05-04 CA CA2982704A patent/CA2982704C/en active Active
- 2016-05-04 DK DK16720421T patent/DK3294740T3/da active
- 2016-05-04 PT PT167204213T patent/PT3294740T/pt unknown
- 2016-05-04 UA UAA201712023A patent/UA120450C2/uk unknown
- 2016-05-04 MX MX2017014033A patent/MX376761B/es active IP Right Grant
- 2016-05-04 ES ES16720421T patent/ES2753777T3/es active Active
- 2016-05-04 PE PE2017002102A patent/PE20171620A1/es unknown
- 2016-05-04 KR KR1020177035298A patent/KR102690131B1/ko active Active
- 2016-05-04 WO PCT/EP2016/059961 patent/WO2016180695A1/en not_active Ceased
- 2016-05-04 CN CN201680026493.3A patent/CN107580596B/zh active Active
- 2016-05-04 HU HUE16720421A patent/HUE045906T2/hu unknown
- 2016-05-04 EP EP16720421.3A patent/EP3294740B1/en active Active
- 2016-05-04 HR HRP20191942TT patent/HRP20191942T1/hr unknown
- 2016-05-04 JP JP2017558397A patent/JP6738352B2/ja active Active
- 2016-05-04 SI SI201630473T patent/SI3294740T1/sl unknown
- 2016-05-04 LT LT16720421T patent/LT3294740T/lt unknown
- 2016-05-04 RS RSP20191351 patent/RS59435B1/sr unknown
- 2016-05-04 MX MX2020010949A patent/MX393198B/es unknown
- 2016-05-04 CR CR20170496A patent/CR20170496A/es unknown
- 2016-05-04 NZ NZ735648A patent/NZ735648A/en not_active IP Right Cessation
- 2016-05-05 AR ARP160101278A patent/AR104528A1/es unknown
- 2016-05-06 TW TW105114192A patent/TWI706954B/zh active
- 2016-05-06 TW TW109131169A patent/TWI768467B/zh not_active IP Right Cessation
- 2016-05-06 US US15/148,309 patent/US9708325B2/en active Active
-
2017
- 2017-06-13 US US15/621,080 patent/US10399983B2/en active Active
- 2017-09-29 CO CONC2017/0009994A patent/CO2017009994A2/es unknown
- 2017-10-09 IL IL254947A patent/IL254947B/en active IP Right Grant
- 2017-10-30 CL CL2017002745A patent/CL2017002745A1/es unknown
- 2017-11-03 PH PH12017502009A patent/PH12017502009A1/en unknown
-
2019
- 2019-08-02 US US16/530,229 patent/US11242345B2/en active Active
-
2020
- 2020-10-14 AU AU2020256348A patent/AU2020256348B2/en not_active Ceased
-
2021
- 2021-02-09 IL IL280769A patent/IL280769B2/en unknown
-
2022
- 2022-06-29 AU AU2022204666A patent/AU2022204666A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20171620A1 (es) | Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas | |
| PE20160686A1 (es) | Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infeccion por virus de la hepatitis b | |
| MX2021005850A (es) | Heterociclos funcionalizados como agentes antivirales. | |
| CL2019000271A1 (es) | Inhibidores de polimerasa hcv. (divisional solicitud 201600493) | |
| PE20171648A1 (es) | Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la capsida del vhb | |
| AR085327A1 (es) | Inhibidores del virus de la hepatitis c | |
| CL2018003492A1 (es) | Hepatitis b agentes antivirales. | |
| PE20142148A1 (es) | Compuestos para el tratamiento y profilaxis de la enfermedad del virus sincicial respiratorio | |
| PE20171341A1 (es) | Compuestos de pirazina para el tratamiento de enfermedades infecciosas | |
| ECSP12011684A (es) | Inhibidores de los virus flaviviridae. | |
| BR112015021027A2 (pt) | compostos terapêuticos | |
| PE20140522A1 (es) | Derivados de nucleosidos 2'- sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
| PE20141558A1 (es) | Derivados de acido benzotiazol-6-il acetico y su uso para tratar una infeccion por vih | |
| CO6561783A2 (es) | Inhibidores del virus flaviviridae | |
| PE20160608A1 (es) | Compuestos de quinolina selectivamente sustituida | |
| PE20170679A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales | |
| CL2020000487A1 (es) | Agentes antivirales contra la hepatitis b. | |
| MA37712A2 (fr) | Inhibiteurs macrocycliques de virus flaviviridae | |
| AR093659A1 (es) | Derivados ciclicos de nucleosidos y usos de los mismos | |
| AR094966A1 (es) | Composiciones farmacéuticas para el tratamiento de infecciones hcv | |
| PE20131165A1 (es) | Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral | |
| EA201591220A1 (ru) | Новые противовирусные агенты против инфекции вирусом гепатита в | |
| PE20141041A1 (es) | Compuestos, metodos y formulaciones parasiticidas | |
| AR078542A1 (es) | Moduladores de gpr40 de pirrolidina | |
| PE20140109A1 (es) | Inhibidores del virus de la hepatitis c |